Did ResMed beat or miss consensus estimates last quarter?

What were the key takeaways from ResMed's earnings call?

What is the market's earnings forecast for ResMed next quarter?

What is ResMed's gross profit margin?

What does ResMed do and what are its main business segments?

What guidance did ResMed's management provide for the next earnings period?

What is the revenue and EPS growth rate for ResMed year over year?

What is ResMed's latest dividend and current dividend yield?

- **Revenue Beat Expectations**: 9% headline growth driven by U.S. device (8%) and mask (12%) resupply, with Europe, Asia masks returning to high single-digit growth.
- **Innovative Product Launches**: AirTouch F30i masks and AI tools (Dawn, Comfort Match) position ResMed as leader in patient comfort and adherence.
- **Gross Margin Expansion**: 280 bps YoY improvement to 62%, with FY26 guidance of 61%-63%.
- **U.S. Manufacturing Expansion**: $1.4 billion cash balance supports $150M/quarter share buybacks and strategic investments in U.S. manufacturing and AI.
- **Strategic Acquisitions Paying Dividends**: VirtuOx and NightOwl driving 8% U.S. device growth, with Europe, Asia masks poised for acceleration.

**【CEO Summary Section】**
- **Revenue Growth**: Q1 FY26 revenue of $1.34 billion, up 9% year-over-year (8% constant currency). U.S., Canada, and Latin America devices grew 8%, masks and other categories 12%; Europe, Asia, and Rest of World devices grew 7% (constant currency), masks and other 4%.
- **Product Launches**: Launched AirTouch F30i full-face masks (F30i Comfort and F30i Clear variants) in Australia and the U.S., featuring fabric-based patient interfaces for comfort and adherence. These masks target 30-40% of patients who breathe through both nose and mouth.
- **AI Innovations**: Introduced Dawn, a generative AI-powered digital assistant on the myAir platform, and Comfort Match, an AI-enabled comfort setting technology. These tools aim to improve patient adherence and outcomes.
- **Manufacturing Expansion**: Announced a third U.S. distribution center in Indianapolis to enhance product velocity and resilience, with 90% of customers receiving shipments within 2 days.
- **Strategic Acquisitions**: Continued integration of VirtuOx (home sleep apnea testing services) and NightOwl, driving 8% U.S. device growth and 12% mask resupply growth.

**【CFO Financial Commentary】**
- **Gross Margin Expansion**: 62% gross margin, up 280 basis points YoY, driven by component cost improvements and logistics efficiencies. FY26 gross margin expected to remain between 61%-63%.
- **Operating Profit**: Operating profit up 19% YoY, with operating margin improving to 36.1% (33.2% prior year). Non-GAAP EPS of $1.08, up 16% YoY.
- **Cash Flow**: $457 million cash flow from operations, with $1.4 billion cash balance. Returned $238 million to shareholders via dividends and buybacks.
- **Restructuring**: $16 million restructuring charge to align with 2030 strategy, impacting SG&A and R&D expenses.

**【Q&A Highlights】**
- **Mask Innovation**: F30i masks leverage fabric technology to improve comfort and adherence, targeting high-margin full-face category. Europe, Asia, and Rest of World masks expected to return to high single-digit growth.
- **U.S. Manufacturing**: Expanding U.S. manufacturing to 60%+ of global volume, including device production, to mitigate geopolitical risks and support Made in America policies.
- **Demand Generation**: CME programs educated 22,000+ PCPs, with 75% intending to change clinical practices. NightOwl and VirtuOx driving 8% U.S. device growth and 12% mask resupply growth.
- **Tax Impact**: Effective tax rate rose to 22.3% due to global minimum tax legislation, partially offset by Singapore R&D credits. FY26 rate expected to remain 21%-23%.
- **Competitive Bidding**: Confident HMEs will bid appropriately, focusing on cost-saving benefits of sleep apnea treatment for Medicare beneficiaries.

ResMed Inc. (RMD) Q1 2026 Earnings Call Transcript

- **Record Q4 Performance**: $1.35B revenue (+10% YoY), 61.4% gross margin (+230bps YoY), and $1.7B FY25 free cash flow.
- **AI-Driven Innovation**: AI reduces R&D time by 90%; 'Dawn' assistant expands to global markets in FY26.
- **Strategic Acquisitions Pay Off**: VirtuOx adds $45M annual run rate; Ectosense/NightOwl wearable HSA test launched in U.S.
- **Shareholder Returns**: $610M returned in FY25; FY26 buybacks at $150M/Q and 13% dividend hike.
- **GLP-1 Synergy**: 11% higher CPAP starts among GLP-1 patients; 3-5% higher adherence at 1-2 years.

**【CEO Summary Section】**
- **Revenue Growth**: Q4 FY25 revenue of $1.35 billion, up 10% YoY (9% in constant currency), driven by device and ReSupply sales across all regions.
- **Gross Margin Expansion**: 230 basis points YoY to 61.4%, fueled by procurement, manufacturing, and logistics efficiencies, with FX contributing ~50% of sequential improvement.
- **AI and Digital Health**: Rolled out AI-powered 'Dawn' assistant in Australia, with plans for global expansion; AI-driven R&D processes reduce development time by 90%.
- **Strategic Acquisitions**: Completed VirtuOx acquisition ($140M) to accelerate home sleep apnea testing; Ectosense and Somnoware integrate into digital health ecosystem.
- **Capital Allocation**: $610M returned to shareholders in FY25 (dividends + buybacks); FY26 share repurchases increased to $150M/Q, with dividend raised 13% to $0.60/share.

**【CFO Financial Commentary】**
- **Non-GAAP EPS**: $1.08, up 23% YoY, with FX adding $0.05/Q.
- **Operating Profit**: $473M (35% margin), up 19% YoY, driven by revenue growth and margin expansion.
- **Cash Flow**: $539M from operations, ending with $1.2B cash balance and $668M gross debt.
- **FY26 Guidance**: Gross margin 61-63%, SG&A 19-20% of revenue, R&D 6-7% of revenue.

**【Q&A Highlights】**
- **Rest of World Growth**: 10% device sales growth in EMEA/Asia, driven by market expansion and VirtuOx integration.
- **VirtuOx Roadmap**: $45M annual run rate; focus on scaling home sleep apnea testing through marketing and partnerships.
- **Competitive Bidding**: CMS likely to maintain status quo; ResMed supports HMEs with Brightree tech and CME programs.
- **GLP-1 Impact**: 11% higher CPAP start rate among GLP-1 patients; 3-5% higher ReSupply adherence at 1-2 years.
- **Gross Margin Risks**: FY26 FX headwinds offset by supply chain efficiencies; AS10/AS11 platform transition completes in FY26.

ResMed Inc. (RMD) Q4 2025 Earnings Call Transcript

- **Revenue Beats Expectations**: +8% growth driven by masks (+12%) and device (+7%) across all regions.
- **Gross Margin Soars**: 59.9% (up 140bps YoY) from manufacturing efficiencies and product mix shifts.
- **Life-Saving Impact**: CPAP reduces mortality by 37% (all-cause) and 55% (cardiovascular), underscoring adherence focus.
- **Share Buybacks Accelerated**: $100M/Q4 buybacks to offset dilution, up from $75M.
- **Tariff Resilience**: U.S. Customs reaffirms medical device tariff exemptions, no material impact.
- **GLP-1 Growth Driver**: CME programs with PCPs prescribing CPAP + GLP-1 drugs show measurable prescription lift.


**【CEO Summary Section】**
- **Revenue Growth**: Q3 FY25 revenue of $1.29B (+8% headline, +9% constant currency), driven by device (+7%) and masks/accessories (+12%) growth across all regions.
- **Gross Margin Expansion**: 59.9% (up 140bps YoY), driven by manufacturing/logistics efficiencies, favorable product mix, and AS10/AS11 platform transitions.
- **New Product Launches**: NightOwl HSA test and VPAP Tx titration platform now commercially available, integrating with Somnoware and AirView for seamless care pathways.
- **Supply Chain Resilience**: $30M U.S. manufacturing expansion in Calabasas, CA to double mask production capacity, supported by $933M cash balance and net cash position.
- **Patient Outcomes**: Lancet study shows CPAP reduces all-cause mortality by 37% and cardiovascular mortality by 55%, reinforcing therapy adherence focus.

**【CFO Financial Commentary】**
- **Non-GAAP EPS**: $2.37 (+11%), excluding $6M investment portfolio write-downs.
- **Operating Cash Flow**: $579M (including $107M tax refund), free cash flow of $472M ex-refund.
- **Share Buybacks**: Increased to $100M/Q4, up from $75M, with $314K shares repurchased in Q3.
- **Dividend Policy**: Quarterly dividend of $0.53/share, supported by strong cash generation.
- **Tax Rate**: 20.1% effective rate, stable with prior quarters.

**【Q&A Highlights】**
- **Tariff Impact**: U.S. Customs reaffirmed medical device tariff exemptions, no material impact expected despite 10% export tariffs.
- **GLP-1 Synergy**: CME education programs for PCPs prescribing CPAP with GLP-1 drugs show measurable prescription increases.
- **Resupply Growth**: Brightree ReSupply programs achieve 13% U.S. masks/accessories growth, targeting 50-100bps above market rates.
- **M&A Strategy**: Seeking tuck-in acquisitions (<5% market cap) aligned with 2030 strategy, focusing on sleep health/digital health adjacents.


ResMed (RMD)-23 Apr 25-2025 Q3 Earnings call transcript

- **Revenue Beat Expectations**: 10% YoY growth driven by 11% gains in devices and masks/accessories.
- **Gross Margin Expansion**: 230bps to 59.2%, targeting 59-60% in H2 FY25.
- **Innovative Product Launches**: AirTouch N30i fabric interface and Apple Vision Pro partnership.
- **GLP-1 Drug Synergy**: 1.2M patients on PAP + GLP-1 show 10% higher adherence, creating new demand pipeline.
- **Wearable Integration**: myAir app data syncing with Apple/Samsung wearables to drive adherence.
- **Share Buybacks**: $75M/QTR to offset dilution, maintaining strong liquidity ($522M cash).

**【CEO Summary Section】**
- Global revenue grew 10% YoY, driven by double-digit growth in devices (11%) and masks/accessories (11%).
- Non-GAAP gross margin expanded 230bps to 59.2%, reflecting manufacturing efficiencies and component cost improvements.
- Launched AirTouch N30i with innovative fabric-based interface and partnered with Apple Vision Pro for Kontor head strap.
- GLP-1 drugs (e.g., Eli Lilly's Zepbound) are creating new patient pathways, with 1.2M patients now on both PAP therapy and GLP-1s, showing 10% higher adherence rates.
- Consumer wearables (Apple Watch, Samsung Galaxy) are raising sleep apnea awareness, with ResMed integrating myAir app data into these platforms.
- FY25 guidance includes 59-60% gross margin range and continued investment in R&D (~6-7% of revenue).

**【CFO Financial Commentary】**
- Q2 revenue: $1.28B (10% YoY), with $2M FX headwind and $15-20M expected Q3 impact.
- Non-GAAP EPS: $1.08 (29% YoY growth), driven by 19% operating profit increase.
- Cash flow from operations: $309M, ending with $522M cash balance.
- Share buybacks: ~$75M/QTR, offsetting dilution from equity vesting.
- FY25 tax rate: 19-21%, down from prior year due to equity compensation benefits.

**【Q&A Highlights】**
- **Currency Impact**: 30bps QoQ margin drag, but 59-60% H2 guidance maintained. FX neutralizes SG&A/R&D benefits.
- **GLP-1 Patient Flow**: Early phase, with Lilly's Zepbound launch in Dec 2024. CME programs targeting GLP-1 prescribers expected to drive demand.
- **ReSupply Growth**: Snap technology adoption accelerating, with 230bps gross margin expansion from ReSupply programs.
- **Software Business**: MEDIFOX (Germany) leading 8% RCG growth, Brightree integration with Snap driving SaaS momentum.
- **RePAP Strategy**: 5-year device replacement cycle driving ~100k units annually, complementing new patient growth.
- **Consumer Tech Synergy**: ResMed masks featured in Samsung Galaxy Watch ads, with myAir app data syncing to Apple/Google wearables.


RMD

RMD fundamentals

Earnings Call

You can ask Aime